Emergent BioSolutions signed a five-year contract with Johnson & Johnson to manufacture the drug substance in a COVID-19 vaccine scheduled for human testing this month. Emergent's Baltimore Bayview facility is an HHS-designated Center for Innovation in Advanced Development and Manufacturing and reportedly can make hundreds of millions of vaccine doses yearly.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.